Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Eligible randomised controlled trials compared drugs used to treat adults with type 2 diabetes. We considered the following drug classes: SGLT-2 inhibitors, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Appendix 1.3 describes the detailed drug names and definitions of control arms (typically standard treatment at the time the trials were conducted, representing the treatment regimens the patient received before the clinician considered adding a new drug). Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug treatment, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible.

We used comprehensive literature search strategies from previously published network meta-analyses in Ovid Medline, Embase, and Cochrane Central to 14 October 2022 (see appendix 1.1 for search strategies). The search added terms for non-steroidal mineralocorticoid receptor antagonists and dual GIP/GLP-1 receptor agonists. The search included reference lists of other identified systematic reviews evaluating cardiovascular and kidney outcomes associated with drugs of interest.

The study performed a pilot test for the study selection process before screening. Pairs of reviewers (QS, KNo, QF, ZQ, and FY) independently screened identified hits at the title and abstract and full text levels, with discrepancies resolved by a senior reviewer (SL).

Using a standardised extraction form, the paired trained reviewers (QS, KNo, YM, QF, ZQ, XZ, XC, ZC, XL, and SH) independently extracted the following data:

A senior reviewer (SL) resolved discrepancies. We prioritised study reported intention-to-treat results or modified intention-to-treat results over per protocol results.

Pairs of reviewers independently assessed the risk of bias (QS, KNo, LG, YJ, YM, AAs, CZ, JPL, KNu, SRC, SG, YG, HZ, QiuY, XL, QinY, and XA). The Cochrane risk-of-bias tool, modified by the CLARITY group at McMaster University, informed risk-of-bias assessmentsfor the following six domains: random sequence generation, allocation concealment, blinding to allocated interventions, missing outcome data, selective outcome reporting, and other concerns. Response options for each item were definitely yes (low risk of bias), probably yes, probably no, and no (high risk of bias). A third team (KNo, QinY, and QS) cross checked the pairs of assessments and summarised the final results, with residual discrepancies resolved by a senior reviewer (SL). ¹⁷

We judged the following outcomes as critical: all cause death, cardiovascular death, non-fatal stroke, end stage kidney disease, and amputation; and the following outcomes as important: non-fatal myocardial infarction, admission to hospital for heart failure, body weight change, health related quality of life, severe hypoglycaemia, severe gastrointestinal events, genital infection, ketoacidosis due to diabetes, and hyperkalaemia leading to admission to hospital. We evaluated the impact on end stage kidney disease using a composite of long term dialysis, kidney transplantation, a sustained estimated glomerular filtration rate <15 mL per minute per 1.73 m, a sustained percentage decline in estimated glomerular filtration rate of at least 40% or a doubling of serum creatinine, or kidney related death.Appendix 1.2 details the definition of outcomes. 2 ¹⁸

We measured the binary outcomes using odds ratios. For continuous outcomes, we measured health related quality of life as standardised mean difference, and body weight in kg as mean difference.

We conducted random effect network meta-analysis using a frequentist graph theoretical approach with the weighted least square estimator and Moore-Penrose pseudoinverse.In principle, we started with the assumption that relative effects were similar across drugs in the same class unless evidence indicated otherwise, and the network nodes are therefore in most cases grouped into drug classes based on their mechanisms. The sole exception in which evidence suggests the starting assumption is inaccurate is the impact of GLP-1 receptor agonists on body weight change.The analysis used the continuity correction to account for zero event by adding 0.5 to all cells of groups for the trials with at least one zero event.The global heterogeneity was evaluated with generalised methods of moments estimate of variance between studies and tested by the design based decomposition of Cochran’s Q statistic.We calculated indirect estimates from the network by node splitting and back calculation methods.For each network loop, we judged the local incoherence considering the clinical and statistical significance of the ratio of direct and indirect estimates. Comparison adjusted funnel plots evaluated global small study effects, which could reflect publication bias. We judged the intransitivity based on distribution comparisons of potential effect modifiers (ie, baseline age, sex, body mass index, HbA1c, the proportion of cardiovascular disease, and duration of diabetes) for each direct comparison and outcome, as well as meta-regressions of these parameters with the treatment effect for each drug and outcome. ^{19 20 21 22 23}

We performed sensitivity analyses, including a bayesian network meta-analysis adjusted by trial duration; a Mantel-Haenszel fixed effect network meta-analysis for rare events; a meta-analysis excluding trials with high risks of bias; a meta-analysis for end stage kidney disease that restricted the definition to a composite of long term dialysis, kidney transplantation, and death from kidney failure; a meta-analysis excluding phase 2 or phase 3 trials; and a meta-analysis pooling study reported hazard ratios for the trials with ≥2 years’ follow-up. ^{24 25}

For trial and aggregated patient characteristics measured as continuous variables, we performed the following four meta-regressions:

The credibility of any apparent subgroup effect (regression coefficient’s credible interval excludes null effect) was rated using the ICEMAN tool.If no credible subgroup effect was indicated, we assumed the constancy of relative effects across populations. ²⁶

Following GRADE (grading of recommendations assessment, development and evaluation) guidance, evidence from direct comparisons started as high certainty evidence and could be rated down for risk of bias, inconsistency, indirectness, and publication bias.Evidence from indirect comparisons could be further rated down for intransitivity. A contribution matrix quantified the proportional contribution of each direct comparison with each indirect and network comparison using the random walk approach.The final certainty for network evidence was rated down for incoherence or imprecision.We rated imprecision following the GRADE guidance.When point estimates proved less than specified minimal important differences established by a previous guideline panel,we rated certainty in little or no effect, otherwise in non-zero effect (ie, null effect threshold). We rated down for imprecision by two levels when the 95% confidence interval crossed more than one threshold of importance (appendices 1.4 and 5). ^{27 28 29 30 3 31}

To categorise the relative impact of interventions, we chose the null effect as the decision threshold and standard treatments as the reference intervention.We initially categorised treatments as different or not different from standard treatments, and subsequently as different or not different from at least one of those with an established difference from standard treatments. This process established five categories of interventions from among the best to among the worst. We then separated these drugs as high or moderate versus low or very low certainty of evidence according to the certainty of evidence relative to standard treatments. ^{32 33}

To better inform clinical decision making, we estimated the anticipated absolute effects of all drugs on the cardiovascular, kidney, and safety outcomes. If valid, we adopted baseline risk estimates applied in a clinical practice guideline that included a systematic review of risk prediction models.We calculated the absolute benefits (number of events per 1000 patients in five years) by applying the relative effects to the baseline risks in five tiers of adults with type 2 diabetes at varying risks of cardiovascular and kidney outcomes: three or fewer cardiovascular risk factors, more than three cardiovascular risk factors, established cardiovascular disease but not chronic kidney disease, established chronic kidney disease but not cardiovascular disease, and established cardiovascular disease and chronic kidney disease. For outcomes not included in the guideline we anticipated baseline risks by pooling the incidence rate in the control arm across trials via the random effect single arm meta-analysis (appendix 5.3), not further stratified by individual risk profiles (eg, risk of genital infections). ³⁴

Given the complexity of presenting 9770 estimates of effect from this network meta-analysis, we elected to primarily present relative and absolute estimates of effect, certainty, and more detailed network meta-analysis results (eg, number of participants and trials for each comparison) through an interactive GRADE summary of findings table, the MATCH-IT tool (). This tool also allows end users to compare any of the treatment options, including change of comparator (eg, finerenoneSGLT-2 inhibitors or GLP-1 receptor agonists for key cardiovascular and kidney outcomes). https://matchit.magicevidence.org/230125dist-diabetes↗ v

For the outcome selection and importance rating as well as the minimal important difference for each outcome, this systematic review referred to a previous guideline and its company systematic review, where the patient partners informed their values and preferences.

The 816 trials that proved eligible enrolled 471 038 participants with a typical mean age in the late 50s, over 50% men, with a mean body mass index of about 30, and a mean HbA1c of about 8.0%. About 60% of the participants had confirmed cardiovascular disease at baseline (,, appendix 2.1, and appendix 2.2). fig 1 table 1

Of the 816 trials, 223 proved at high risk of bias for at least one of six domains, most commonly because of lack of blinding (62%), missing outcome data (26%), and allocation concealment (25%) (appendix 3). The evidence did not suggest global publication bias and intransitivity for any outcome (appendix 4.7), nor did the results suggest relevant global inconsistency or incoherence in outcomes except for health related quality of life, body weight change, and amputation (appendices 4.4, 4.5, and 4.6).

shows the network plot with connections between each drug in all included trials for any outcome, appendix 4.1 shows other network plots for each outcome, and appendix 4.3 shows the network estimates with certainty of evidence for each comparison for each outcome. Appendix 5 details the assessments of GRADE certainty of evidence for the direct, indirect, and network comparisons.shows the comparative benefits and harms (excluding weight change, see below) of all drugs of interest through their relative estimates of effect, categorised from the most effective to the most harmful, taking certainty of evidence into account.illustrates the anticipated absolute benefits and harms of all drugs for adults with type 2 diabetes and chronic kidney disease (selected because randomised trials on finerenone were restricted to this population).shows the effects of these drugs on weight change. Figure 2 Figure 3 Figure 4 Figure 5

The MATCH-IT tool () provides an interactive view of the anticipated absolute effects for all populations at varying risks of cardiovascular and kidney outcomes. These data are also available in appendix 6 and - with even more details, in another interactive online tool (). Below, we summarise the relative effects for cardiovascular, kidney, and harm outcomes for all drugs and provide examples of anticipated absolute effects for selected outcomes; all subsequent estimates refer to the comparison with standard treatments. https://matchit.magicevidence.org/230125dist-diabetes↗ https://qingys.shinyapps.io/data_visualization↗

The analysis included 257 trials with 342 237 participants and 15 371 events for all cause mortality, and 144 trials with 275 679 participants and 9120 events for cardiovascular death. SGLT-2 inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause mortality, and cardiovascular death (SGLT-2 inhibitors: 0.86, 0.80 to 0.94; GLP-1 receptor agonists: 0.87, 0.81 to 0.94; both high certainty). Non-steroidal mineralocorticoid receptor antagonists probably reduce all cause mortality (0.89, 0.79 to 1.00; moderate certainty) and possibly reduce cardiovascular death (0.88, 0.75 to 1.02; low certainty). Metformin possibly reduces all cause mortality (0.84, 0.67 to 1.04; low certainty) and might have little or no effect on cardiovascular death. DPP-4 inhibitors probably have little or no effect on cardiovascular death (moderate certainty). Sulfonylureas possibly increase all cause mortality (low certainty) and might have little or no effect on cardiovascular death. Other drugs might have little or no or uncertain effect on mortal outcomes (low to very low certainty;and appendix 5). fig 3

This analysis included 209 trials with 293 042 participants and 8906 events for non-fatal myocardial infarction, and 178 trials with 283 728 participants and 4878 events for non-fatal stroke. SGLT-2 inhibitors reduce non-fatal myocardial infarction (odds ratio 0.90, 95% confidence interval 0.82 to 0.98; high certainty)—as, probably, do GLP-1 receptor agonists (0.91, 0.85 to 0.98; moderate certainty) and, possibly, metformin (0.86, 0.68 to 1.09; low certainty). GLP-1 receptor agonists are the only drug class that convincingly reduces non-fatal stroke (0.85, 0.77 to 0.94; high certainty). Other drugs might have little or no or uncertain effects on non-fatal myocardial infarction or stroke, relative to standard treatments (low to very low certainty;and appendix 5). fig 3

The analysis included 142 trials with 252 055 participants and 6681 events. SGLT-2 inhibitors (odds ratio 0.66, 95% confidence interval 0.60 to 0.73; high certainty) decrease admission to hospital for heart failure as, probably, do GLP-1 receptor agonists (0.91, 0.83 to 0.99; moderate certainty) and finerenone (0.78, 0.66 to 0.92; moderate certainty). SGLT-2 inhibitors and finerenone are among the most effective drugs in this regard and SGLT-2 inhibitors are probably superior to GLP-1 receptor agonists (moderate certainty). Thiazolidinediones probably increase admission to hospital due to heart failure (1.54, 1.27 to 1.88; moderate certainty). Metformin and other drugs might have little or no effect, or uncertain effects (low or very low certainty;and appendix 5). fig 3

The analysis included 54 trials with 209 754 participants and 6972 events. Compared with standard treatments, SGLT-2 inhibitors (odds ratio 0.61, 95% confidence interval 0.55 to 0.67; moderate certainty), GLP-1 receptor agonists (0.83, 0.75 to 0.92; moderate certainty), and finerenone (0.83, 0.75 to 0.92; moderate certainty) probably reduce end stage kidney disease. We rated down the certainty of evidence to moderate owing to indirectness, a result of our composite outcome of end stage kidney disease driven by variable reporting of kidney outcomes in the trials. SGLT-2 inhibitors are among the most effective drugs and are possibly superior to GLP-1 receptor agonists and finerenone (low certainty). Other drugs might have little or no effect, or uncertain effects on end stage kidney disease, relative to standard treatment (very low to low certainty;and appendix 5). fig 3

We analysed 33 trials with 18 588 participants using 13 types of questionaries (appendix 1.2). SGLT-2 inhibitors, GLP-1 receptor agonists, and tirzepatide probably improve health related quality of life with standardised mean differences ranging from 0.17 to 0.39 (moderate certainty), which did not surpass the minimal important difference (1.7 to 3.9 points in the 36-item short form survey; minimal important difference 10 points). DPP-4 inhibitors probably have little or no effect, and other drugs might have little or uncertain impact on health related quality of life (low or very low certainty;and appendix 5). fig 3

We analysed 531 trials with 279 118 participants.shows that tirzepatide is the most effective drug for reducing body weight (mean reduction 8.57 kg, 95% confidence interval 7.75 to 9.40), followed by individual GLP-1 receptor agonists, SGLT-2 inhibitors (class effect), and metformin with intermediate effects (mean reduction, range 4.62 to 0.72 kg), all high to moderate certainty). Two classes of drugs probably have the biggest effect size in increasing body weight: thiazolidinediones (2.81 kg, moderate certainty) and basal insulin (2.15 kg, moderate certainty). A third, basal bolus insulin, may have a similar effect (increase 3.26 kg, low certainty). Another four drugs have intermediate effects on body weight: sulfonylureas probably increase body weight by 1.78 kg (moderate certainty), meglitinides may increase body weight by 1.26 kg (low certainty), bolus insulin probably increases body weight by 1.01 kg (moderate certainty), and DPP-4 inhibitors probably increase body weight minimally by 0.28 kg (moderate certainty). Other drugs might have little or no effect on body weight (low to very low certainty;and appendix 5). Figure 5 fig 5

We analysed 202 trials with 302 457 participants and 5595 events. Sulfonylureas (odds ratio 5.22, 95% confidence interval 3.88 to 7.01) and basal bolus insulin (4.94, 1.06 to 22.96) probably increase the risk of severe hypoglycaemic events (moderate certainty), with likely smaller increases in risk with basal insulin (2.38, 1.82 to 3.12), bolus insulin (2.46, 1.31 to 4.63), and DPP-4 inhibitors (1.11, 1.00 to 1.23), with and without the contamination of other treatments. Meglitinides and thiazolidinediones may increase the risk of severe hypoglycaemic events (low certainty). SGLT-2 inhibitors and GLP-1 receptor agonists do not increase the risk of severe hypoglycaemic events (high certainty). Finerenone is probably associated with fewer severe hypoglycaemia than the standard treatments (0.64, 0.43 to 0.96, moderate certainty). Other drugs might have little to no effect compared with standard treatments (low to very low certainty;and appendix 5). fig 3

We analysed 37 trials with 65 283 participants and 1661 events. Tirzapetide (odds ratio 4.59, 95% confidence interval 1.89 to 11.14) and GLP-1 receptor agonists (1.97, 1.39 to 2.80) probably increase the risk of severe gastrointestinal adverse events (moderate certainty). Other drugs might have little or no effects compared with standard treatments (low to very low certainty;and appendix 5). fig 3

We analysed 94 trials with 103 111 participants and 2396 events. SGLT-2 inhibitors increase genital infection (odds ratio 3.30, 95% confidence interval 2.88 to 3.78; high certainty). Sulfonylureas may reduce the risk of a genital infection (0.52, 0.36 to 0.75; low certainty). Other drugs might have little to no effect compared with standard treatments (low to very low certainty;and appendix 5). fig 3

We analysed 18 trials with 107 503 participants and 1150 events. SGLT-2 inhibitors probably increase the risk of amputation (odds ratio 1.27, 95% confidence interval 1.01 to 1.61, moderate certainty); other drugs do not (high to very low certainty;and appendix 5). With an estimated baseline risk of 1%, treatment with SGLT-2 inhibitors in 1000 patients for five years probably results in three additional amputations (95% confidence interval 0 to 6;and appendix 6). fig 3 fig 4

We analysed 36 trials with 138 322 participants and 265 events. SGLT-2 inhibitors increase the risk of ketoacidosis due to diabetes (odds ratio 2.07, 95% confidence interval 1.44 to 2.98; high certainty); other drugs do not (high to very low certainty;and appendix 5). With an estimated baseline risk of 0.2%, treatment with SGLT-2 inhibitors in 1000 patients for five years probably results in two more events with ketoacidosis due to diabetes (95% confidence interval 1 to 4;and appendix 6). fig 3 fig 4

We analysed two trials with 12 999 participants and 71 events for the non-steroidal mineralocorticoid receptor antagonists, which probably increase the risk of hyperkalaemia leading to admission to hospital (odds ratio 5.92, 95% confidence interval 3.02 to 11.62; moderate certainty). With an estimated baseline risk of 0.2%, treatment with non-steroidal mineralocorticoid receptor antagonists in 1000 patients for five years probably results in 10 additional events (95% confidence interval 4 to 21;and appendix 6). fig 4

Our study did not identify any credible subgroup effects (appendix 7) and all sensitivity analyses confirmed the robustness of our findings (appendix 8).

This network meta-analysis comprehensively summarises the benefits and harms of available drug treatments for type 2 diabetes, including the two recently available drugs finerenone and tirzepatide. Among all drug classes, SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone show benefits in reducing all cause mortality, admission to hospital due to heart failure (SGLT-2 inhibitors and—probably—finerenone are the most effective drug treatments), and end stage kidney disease (SGLT-2 inhibitors are the most effective drug treatments). Only GLP-1 receptor agonists convincingly reduce non-fatal stroke. SGLT-2 inhibitors, GLP-1 receptor agonists, and tirzepatide improve health related quality of life, but did not reach the threshold for minimal important differences, suggesting trivial effects. As illustrated in the MATCH-IT tool, the absolute benefits of these drugs vary greatly in people with type 2 diabetes depending on baseline risks for cardiovascular and kidney outcomes(appendix 6). Trustworthy clinical practice guidelines should provide risk stratified recommendations that could differ in direction and strength, reserving these drugs to adults at elevated risk for cardiovascular and kidney outcomes. ^{2 3 3}

Our work represents the most comprehensive systematic review and network meta-analysis assessing all pertinent drug classes for type 2 diabetes treatment. An international multidisciplinary team shaped the study question and protocol, optimising its relevance to current clinical practice. Our study incorporated current and rigorous approaches to network meta-analysiss and GRADE assessment.Results provide policy makers and healthcare professionals with quick access to summaries of the effectiveness and safety of all available drug classes for diabetes treatments. ^{31 32}

Limitations of our systematic review and network meta-analysis are largely driven by the available evidence. Firstly, for many outcomes that are important to patients, we found low to very low certainty evidence for the oldest as well as the newest classes of drugs, including metformin, sulfonylureas, tirzepatide, and non-steroidal mineralocorticoid receptor antagonists. Secondly, this network meta-analysis cannot answer a highly relevant question: what are the benefits and harms of coadministration of SGLT-2 inhibitors, GLP1 receptor agonists, and finerenone? Nevertheless, observational studies and post hoc analyses of trials suggest cardiovascular and kidney benefits of the combination of SGLT-2 inhibitors, finerenone, and GLP-1 receptor agonists.Thirdly, owing to sparse direct evidence and limited reporting of outcomes important to patients, we adopted a composite outcome definition for end stage kidney disease that included a surrogate component. This resulted in moderate certainty of evidence for the effects of all drugs on end stage kidney disease, given the inherent indirectness. Fourthly, this study did not consider the dose-response of each drug. In future studies it could be interesting to explore potential dose-response effects for drugs such as GLP-1 receptor agonists. Fifthly, the exclusion of all non-English language literature might introduce potential publication bias, which in this study was adjusted by trim-and-fill analyses. ^{35 36}

Finerenone is the first non-steroidal mineralocorticoid receptor antagonist likely to reduce all cause mortality and admission to hospital for heart failure and improve kidney outcomes in people living with type 2 diabetes. Finerenone is an alternative to SGLT-2 inhibitors and GLP-1 receptor agonists in patients with concomitant chronic kidney disease, but results provide only indirect evidence for other populations.A recent analysis, however, suggests that the relative effect on all cause mortality of finerenone is not associated with either baseline estimated glomerular filtration rate or urine albumin-creatinine ratio; thus, effects of finerenone could also apply to patients with type 2 diabetes without chronic kidney disease.Regarding the use of finerenone in patients without diabetes or kidney disease, an ongoing cardiovascular outcome trial of participants with congestive heart failure with or without type 2 diabetes or chronic kidney disease (FINEARTS-HF) is expected to conclude in 2024 and will provide relevant evidence. ^{4 5 37 38 39}

Although finerenone results in a fivefold relative increase in hyperkalaemia leading to admission to hospital, the absolute numbers of admissions to hospitals were very low. The absolute effects of hyperkalaemia (10 additional events per 1000 patients treated for five years) are, for most patients with type 2 diabetes and chronic kidney disease, of less importance than the benefits of 16 fewer deaths, 21 fewer admissions to hospital for heart failure, and 14 fewer cases of end stage kidney disease. Nevertheless, for patients at elevated baseline risk of hyperkalaemia, clinicians should closely monitor serum potassium when prescribing finerenone. Such patients include those taking drug treatments that could elevate serum potassium such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and angiotensin receptor-neprilysin inhibitors. ⁴⁰

Tirzepatide, the only dual GIP/GLP-1 receptor agonist currently available, improves quality of life and reduces body weight with a greater effect than any other drugs or drug classes. GLP-1 receptor agonists also reduce body weight, with semaglutide being the most effective drug in people with type 2 diabetes, as previously established in patients with overweight and obesity.Whereas tirzepatide might be particularly attractive for people with type 2 diabetes seeking body weight loss, we could not show its benefits for cardiovascular and kidney outcomes; these are being explored in an ongoing cardiovascular outcome trial with results expected in 2025.GLP-1 receptor agonists are safe except that an average of 40 patients per 1000 withdraw from these drug treatments because of severe gastrointestinal adverse events. Tirzepatide also causes 133 patients per 1000 to withdraw owing to severe gastrointestinal adverse events. These findings exemplify the need to carefully balance benefits and harms across all patient outcomes for new diabetes drugs, individualised to patients’ characteristics, values, and preferences. ^{20 41}

Our results raise concerns about the use of some well established drugs for glucose lowering in adults with type 2 diabetes. In particular, sulfonylureas may increase all cause mortality (low certainty), and thiazolidinediones probably increase admission to hospital due to heart failure (moderate certainty). Clinicians should be cautious in prescribing these drugs, especially to those at higher baseline risks for such outcomes. An additional new finding in our review is that DPP-4 inhibitors, in addition to sulfonylurea and insulin, show a probable intermediate increased risk of severe hypoglycaemia (moderate certainty). Since laboratory studies do not support the hypoglycaemic risk caused by the monotherapy of DPP-4 inhibitors,for people receiving combined therapy, clinicians should consider reducing the dose of insulin or sulfonylureas when adding these drugs. ⁴²

Consistent with previous systematic reviews,SGLT-2 inhibitors increase the risk of genital infection, ketoacidosis due to diabetes, and, probably, amputation. The minimal absolute increase we have estimated (two additional ketoacidoses and three additional amputations among 1000 people treated with SGLT-2 inhibitors for five years) warrants a trade-off against established cardiovascular and kidney benefits, again most pronounced in patients at increased cardiorenal risk. This finding is in line with the decision made in 2020 by the US Food and Drug Administration to remove the boxed warning for canagliflozin. ^{2 43 44}

Keeping pace with the growing number of published randomised trials in adults with type 2 diabetes, this network meta-analysis finds highly heterogeneous benefits and drug specific harms across 13 drug classes. Beyond confirming the substantial cardiovascular and kidney benefits of SGLT-2 inhibitors and GLP-1 receptor agonists—with absolute effects highly dependent on patient risk profiles—we find that finerenone, the drug recently made available, displays quite similar benefits to SGLT-2 inhibitors and GLP-1 receptor agonists. Tirzepatide shows superior benefits on weight loss than SGLT-2 inhibitors and GLP-1 receptor agonists. These results and other key findings of our comprehensive systematic review highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.